Chiltern: The CRO Future Is Mid-Sized
Executive Summary
In remaining private, and neither aspiring to become--or to merge into--a global organization, nor interested in being a specialty CRO, Chiltern is bucking the trend of an industry which over the last decade has seen considerable consolidation at the top accompanied by a proliferation of much smaller niche players. The company's strategy of balancing customer-focused, cost efficient services with the ability to run pan-European/US clinical trials seems well-aimed to capture the business of the emerging and mid-size pharmaceutical companies that will likely be the most prolific source of new innovative drugs over the next decade.
You may also be interested in...
AureoGen Biosciences Inc.
Formed by Kalamazoo-based Pharmacia alumni, AureoGen Biosciences Inc. is genetically engineering cyclic peptides to create second-generation, resistance-proof anti-infective and anti-fungal therapeutics.
Pain Therapeutics
Pain seems as close to a sure bet as the pharmaceutical industry has to offer. Forecasts call for the worldwide analgesic market, already $38 billion in 2002, to grow at a 20% annual clip, nearly doubling to $75 billion by the year 2010. For new drug developers, pain also has the advantage of offering clearly definable endpoints-less pain-and a relatively short duration for clinical trials. No surprise then that more than 200 companies have a hand in developing or marketing pain therapeutics. Among them, the three young companies profiled here-AlgoRx Pharmaceuticals Inc., Algos Therapeutics Inc., and TheraQuest Biosciences LLC.
Ambrx Inc.
Ambrx is using its technology for engineering proteins with novel amino acids--beyond the 20 that oocur in nature--to enhance the properties of proteins whose potential therapeutic uses, as well as liabilities, are known.